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Letter to the editor
The Theoretical Scenario 
Experienced in a Real-Life 
Case of Ulcerative Colitis 




We have read the recently pub-
lished article by Al Draiweesh et  al.1 
studying the safety of combination 
therapy in patients with inflammatory 
bowel diseases and primary sclerosing 
cholangitis (PSC) after liver trans-
plantation with great interest. It is es-
sential to have wide insight regarding 
biological and antirejection combina-
tion therapy. However, there are some 
small but important details in the pub-
lication that need to be clarified by pre-
senting our case.
Theoretically, the typical scenario 
is ulcerative colitis (UC) and associated 
PSC leading to liver transplantation. 
Therefore, current British Society of 
Gastroenterology guidelines state that 
colitis should be sought in all patients 
with PSC using colonoscopy with bi-
opsies.2 In our case, liver transplanta-
tion was performed on a patient at age 
16 after a 6-year history of UC and 
2  years of PSC. His colonoscopic pic-
tures consequently revealed endoscopic 
and histological ulcerative pancolitis 
with milder activity in the rectum. 
According to the current literature, 
PSC can be accompanied by the rectal-
sparing type of UC. This coexistence is 
suggested to result in a lack of response 
to pharmacotherapies.3 Therefore, 
bowel-selective vedolizumab (VDZ) was 
started for the patient at age 19; there 
was no previous biological need during 
pediatric care. The case series of Al 
Draiweesh et al.1 contains a surprisingly 
high number of patients with Crohn di-
sease. However, about half  of the cases 
were reclassified after ileal pouch anal 
anastomosis surgery, probably because 
of CD-like pouchitis. Coexisting UC 
and PSC with unusual clinical and endo-
scopic picture and drug-refractoriness 
can cause differential diagnostic chal-
lenges even for experienced medical cen-
ters even after surgery.
Liver transplantation performed 
before age 18 can be associated with 
bad drug adherence. Within 6 months 
after VDZ introduction, the patient re-
quired urgent hospitalization because 
of  icterus and threatening rejection 
because of  poor drug intake. Luckily, 
symptoms alleviated after dose escala-
tion of  antirejection therapy and ade-
quate steroid use (3 x 1g intravenous 
methylprednisolone). By this time, 
our patient had already developed re-
current PSC proven by liver biopsy. 
He has not experienced serious infec-
tions, malignancy, or hepatic failure 
since then.
Instructively, despite mild clin-
ical activity, continuous endoscopic and 
histological activity was observed with 
transfusion-requiring anemia and a 
subtherapeutic serum VDZ level (<2 μg/
mL), while the anti-VDZ antibody level 
also remained low (<35  ng/mL) after 
6 months of therapy.
To summarize, we revealed the 
importance of studying the current lit-
erature in rare cases to ease patient 
management even by experienced med-
ical centers.
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